左卡尼汀联合促红细胞生成素对治疗维持性血透肾性贫血临床观察  

Levocarnitine Combined with Erythropoietin in Treatment of Renal Anemia in Hemodialysis

作　　者：冷彦飞[1] 曹昉[1] 李雄[1] 李磊[1] 

机构地区：[1]凉山彝族自治州第一人民医院肾内科,四川西昌615000

出　　处：《四川医学》2016年第7期742-744,共3页Sichuan Medical Journal

摘　　要：目的观察左卡尼汀联合促红细胞生成素治疗维持性血透肾性贫血的疗效。方法本文选取2013年12月至2016年2月我院收治的110例维持性血透肾性贫血患者作为研究对象,随机分成治疗组和对照组,各55例。其中对照组患者采用促红细胞生成素进行治疗,治疗组患者在此基础上联合左卡尼汀进行治疗,比较两组患者临床治疗效果。结果治疗组BMI、HB、HCT以及ALB明显高于对照组,差异有统计学意义(P<0.05);每周外源性人重组促红细胞生成素用量明显低于对照组,差异有统计学意义(P<0.05)。结论左卡尼汀联合促红细胞生成素治疗维持性血透肾性贫血疗效较单独使用促红素效果好。Objective To observe the curative effect of levocarnitine combined with erythropoietin in the treatment of maintenance hemodialysis renal anemia. Methods 110 cases of maintenance hemodialysis patients with renal anemia in our hospital from December 2013 to February 2016 were selected as the research object,and they were randomly divided into treatment group and control group,each of 55 cases. In between patients of control group were treated with erythropoietin,while patients of the treatment group were combined with Levocarnitine treatment on the basis of this,compared the two groups of patients with clinical curative effect. Results The BMI,HB,HCT and ALB of the treatment group were significantly higher than those in the control group（ P0. 05）. And the dosage of exogenous recombinant human erythropoietin was significantly lower than that of the control group（ P0. 05）. Conclusion The curative effect of levocarnitine combined with erythropoietin in the treatment of maintenance hemodialysis renal anemia is better than the use of erythropoietin alone.

关 键 词：左卡尼汀 促红细胞生成素 维持性血透肾性贫血 

分 类 号：R692.5[医药卫生—泌尿科学]